Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Repligen Corporation before investing.

In this article, we go over a few key elements for understanding Repligen Corporation’s stock price such as:

• Repligen Corporation’s current stock price and volume
• Why Repligen Corporation’s stock price changed recently
• Upgrades and downgrades for RGEN from analysts
• RGEN’s stock price momentum as measured by its relative strength

About Repligen Corporation (RGEN)

Before we jump into Repligen Corporation’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Want to learn more about Repligen Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Repligen Corporation.

Repligen Corporation’s Stock Price as of Market Close

As of January 30, 2026, 4:00 PM, CST, Repligen Corporation’s stock price was $149.370.

Repligen Corporation is down 4.48% from its previous closing price of $156.370.

During the last market session, Repligen Corporation’s stock traded between $148.840 and $157.440. Currently, there are approximately 56.27 million shares outstanding for Repligen Corporation.

Repligen Corporation’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Repligen Corporation Stock Price History

Repligen Corporation’s (RGEN) price is currently down 8.84% so far this month.

During the month of January, Repligen Corporation’s stock price has reached a high of $175.770 and a low of $148.840.

Over the last year, Repligen Corporation has hit prices as high as $175.770 and as low as $102.965. Year to date, Repligen Corporation’s stock is down 8.84%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Repligen Corporation Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of January 30, 2026, there were 4 analysts who downgraded Repligen Corporation’s stock and 8 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Repligen Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Repligen Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Repligen Corporation’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Repligen Corporation (RGEN) by visiting AAII Stock Evaluator.

Relative Price Strength of Repligen Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 30, 2026, Repligen Corporation has a weighted four-quarter relative price strength of -3.83%, which translates to a Momentum Score of 37 and is considered to be Weak.

Want to learn more about how Repligen Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Repligen Corporation Stock Price: Bottom Line

As of January 30, 2026, Repligen Corporation’s stock price is $149.370, which is down 4.48% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Repligen Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.